These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28287331)

  • 1. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.
    Río J; Rovira À; Tintoré M; Otero-Romero S; Comabella M; Vidal-Jordana Á; Galán I; Castilló J; Arrambide G; Nos C; Tur C; Pujal B; Auger C; Sastre-Garriga J; Montalban X
    Mult Scler; 2018 Mar; 24(3):322-330. PubMed ID: 28287331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
    Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
    Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients.
    Romeo M; Martinelli V; Rodegher M; Perego E; Maida S; Sormani MP; Comi G;
    Eur J Neurol; 2015 Jun; 22(6):973-80. PubMed ID: 25846708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Goodin DS; Reder AT; Traboulsee AL; Li DK; Langdon D; Cutter G; Cook S; O'Donnell T; Kremenchutzky M; Oger J; Koelbach R; Pohl C; Wicklein EM;
    Mult Scler; 2019 May; 25(6):837-847. PubMed ID: 29761737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing response to interferon-β in a multicenter dataset of patients with MS.
    Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
    Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    Prosperini L; Mancinelli C; Haggiag S; Cordioli C; De Giglio L; De Rossi N; Galgani S; Rasia S; Ruggieri S; Tortorella C; Pozzilli C; Gasperini C
    J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):271-277. PubMed ID: 31974130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
    Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
    Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term evolution of multiple sclerosis disability in the treatment era.
    ; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
    Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scoring treatment response in patients with relapsing multiple sclerosis.
    Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N
    Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.